This suggests that nivolumab-bound CD8+ T cells in the responder have a cytotoxic and progenitor-like phenotype (Ghorani et al., 2020; Miller et al., 2019; Wang et al., 2019; Kallies et al., 2020; Khan et al., 2019; Sekine et al., 2020; Yao et al., 2019; Zhao et al., 2021) and are likely tumor-reactive (Duhen et al., 2018; Simoni et al., 2018) (Table S5), despite upregulating markers of dysfunction. Here, CD8A is linked to neoplasm.